[go: up one dir, main page]

MX2013006234A - Metodo para la produccion de glicoproteinas recombinantes con semivida en circulacion incrementada en celulas de mamifero. - Google Patents

Metodo para la produccion de glicoproteinas recombinantes con semivida en circulacion incrementada en celulas de mamifero.

Info

Publication number
MX2013006234A
MX2013006234A MX2013006234A MX2013006234A MX2013006234A MX 2013006234 A MX2013006234 A MX 2013006234A MX 2013006234 A MX2013006234 A MX 2013006234A MX 2013006234 A MX2013006234 A MX 2013006234A MX 2013006234 A MX2013006234 A MX 2013006234A
Authority
MX
Mexico
Prior art keywords
life
production
circulatory half
recombinant glycoproteins
mammalian cells
Prior art date
Application number
MX2013006234A
Other languages
English (en)
Inventor
Michael J Betenbaugh
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46457991&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2013006234(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Publication of MX2013006234A publication Critical patent/MX2013006234A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/005Glycopeptides, glycoproteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/1048Glycosyltransferases (2.4)
    • C12N9/1081Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18Carboxylic ester hydrolases (3.1.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y204/00Glycosyltransferases (2.4)
    • C12Y204/01Hexosyltransferases (2.4.1)
    • C12Y204/01214Glycoprotein 3-alpha-L-fucosyltransferase (2.4.1.214)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y204/00Glycosyltransferases (2.4)
    • C12Y204/99Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C12Y204/99001Beta-galactoside alpha-2,6-sialyltransferase (2.4.99.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/01Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01008Cholinesterase (3.1.1.8), i.e. butyrylcholine-esterase

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se proporcionan en la presente métodos y sistemas de expresión recombinante para la producción de glicoproteínas recombinantes que tienen un contenido de ácido siálico aumentado y contienen predominantemente enlaces de ácido alfa 2-6 siálico. También se proporcionan en la presente glicoproteínas recombinantes que tienen una semivida en circulación in vivo aumentada. Una aplicación potencial de las glicoproteínas descritas en la presente es para el tratamiento y profilaxis de la intoxicación por neurotoxinas.
MX2013006234A 2011-01-06 2012-01-06 Metodo para la produccion de glicoproteinas recombinantes con semivida en circulacion incrementada en celulas de mamifero. MX2013006234A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161430256P 2011-01-06 2011-01-06
PCT/US2012/020535 WO2012094627A2 (en) 2011-01-06 2012-01-06 Method of production of recombinant glycoproteins with increased circulatory half-life in mammalian cells

Publications (1)

Publication Number Publication Date
MX2013006234A true MX2013006234A (es) 2013-08-01

Family

ID=46457991

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013006234A MX2013006234A (es) 2011-01-06 2012-01-06 Metodo para la produccion de glicoproteinas recombinantes con semivida en circulacion incrementada en celulas de mamifero.

Country Status (10)

Country Link
US (2) US20130243744A1 (es)
EP (1) EP2661492B1 (es)
CN (2) CN107267459A (es)
AU (1) AU2012204241A1 (es)
BR (1) BR112013016447A2 (es)
CA (1) CA2817765A1 (es)
DK (1) DK2661492T3 (es)
MX (1) MX2013006234A (es)
SG (1) SG190260A1 (es)
WO (1) WO2012094627A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
ES2733248T3 (es) 2012-01-11 2019-11-28 Sigma Aldrich Co Llc Producción de proteínas recombinantes con glicoformas simples
KR20220013460A (ko) * 2014-03-04 2022-02-04 시그마-알드리치 컴퍼니., 엘엘씨 바이러스 내성 세포 및 이의 용도
WO2015142679A1 (en) * 2014-03-16 2015-09-24 Yvonne Rosenberg Production of highly thermally stable recombinant cholinesterases for the detection, detoxification and decontamination of organophosphorus compounds
US10053671B2 (en) 2014-06-20 2018-08-21 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
US20170306046A1 (en) 2014-11-12 2017-10-26 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
MD3227325T2 (ro) * 2014-12-01 2024-09-30 Ferring Bv Compoziții de inhibitor selectiv trans-semnalizare de IL-6
DK3226888T3 (da) 2014-12-01 2021-07-12 Ferring Bv Administration af en selektiv inhibitor af il-6-trans-signalering
EP3230438B1 (en) * 2014-12-12 2024-12-04 University of Copenhagen N-glycosylation
EP3042952A1 (en) * 2015-01-07 2016-07-13 CEVEC Pharmaceuticals GmbH O-glycan sialylated recombinant glycoproteins and cell lines for producing the same
IL302822A (en) * 2015-11-12 2023-07-01 Seagen Inc Glycan-interacting compounds and methods of use
JP2019530672A (ja) * 2016-09-13 2019-10-24 バイエル・ヘルスケア・エルエルシーBayer HealthCareLLC 第viia因子グリコフォーム
US11401330B2 (en) 2016-11-17 2022-08-02 Seagen Inc. Glycan-interacting compounds and methods of use
BR112019018043A2 (pt) 2017-03-03 2020-04-07 Seattle Genetics Inc método de tratamento de câncer, e, conjugado de anticorpo-fármaco
EP3570871B1 (en) 2017-03-20 2020-11-18 H. Hoffnabb-La Roche Ag Method for in vitro glycoengineering of an erythropoiesis stimulating protein
WO2019084310A1 (en) 2017-10-25 2019-05-02 Yoshihiro Kawaoka HAS RECOMBINANT INFLUENZA VIRUSES STABILIZED FOR EGG REPLICATION
CN108659095A (zh) * 2018-05-18 2018-10-16 上海药明生物技术有限公司 一种使唾液酸含量稳定的方法
WO2020033527A2 (en) 2018-08-07 2020-02-13 Wisconsin Alumni Research Foundation (Warf) Recombinant biologically contained filovirus vaccine
EP3840780A1 (en) 2018-08-20 2021-06-30 Wisconsin Alumni Research Foundation Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (ha) protein
EP3921413A1 (en) * 2019-02-08 2021-12-15 Wisconsin Alumni Research Foundation (WARF) Humanized cell line
WO2020223699A1 (en) 2019-05-01 2020-11-05 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
WO2021041624A2 (en) 2019-08-27 2021-03-04 Yoshihiro Kawaoka Recombinant influenza viruses with stabilized ha for replication in eggs
WO2021195410A1 (en) 2020-03-25 2021-09-30 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses
CN117587020B (zh) * 2024-01-18 2024-04-02 中国人民解放军东部战区总医院 抑制ST3GAL1基因表达的shRNA及其应用
CN118755805A (zh) * 2024-09-06 2024-10-11 天津舍为斯生物技术有限公司 一种唾液酸化酶qPCR芯片及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204431B1 (en) * 1994-03-09 2001-03-20 Abbott Laboratories Transgenic non-human mammals expressing heterologous glycosyltransferase DNA sequences produce oligosaccharides and glycoproteins in their milk
US20020045207A1 (en) * 1997-10-31 2002-04-18 Lynne A. Krummen Glycoprotein production process
MXPA04003333A (es) * 2001-10-10 2006-02-22 Neose Technologies Inc Remodelado y glicoconjugacion de peptidos.
AU2002365933A1 (en) 2001-11-14 2003-09-02 Joseph D. Mosca Production of recombinant therapeutic bioscavengers against chemical and biological agents
EP1465987B1 (en) * 2001-12-07 2008-01-23 Crucell Holland B.V. Production of viruses, viral isolates and vaccines
US20070111279A1 (en) * 2002-11-13 2007-05-17 Procell, Inc. Production of recombinant therapeutic bioscavengers against chemical and biological agents
EP2115151B1 (en) * 2006-12-28 2014-05-07 Janssen Biotech, Inc. Methods and vectors for generating asialylated immunoglobulins
DK2195444T3 (en) * 2007-10-12 2015-08-24 Sigma Aldrich Co Llc Cell line and methods for enhanced sialylation of glycoprotein.
EP2389586B2 (en) * 2009-01-22 2018-01-24 Momenta Pharmaceuticals, Inc. Galactose-alpha-1,3-galactose-containing n-glycans in glycoprotein products derived from cho cells

Also Published As

Publication number Publication date
WO2012094627A3 (en) 2012-10-04
EP2661492A2 (en) 2013-11-13
BR112013016447A2 (pt) 2019-09-24
WO2012094627A2 (en) 2012-07-12
CN107267459A (zh) 2017-10-20
DK2661492T3 (en) 2018-01-15
EP2661492B1 (en) 2017-10-04
SG190260A1 (en) 2013-06-28
CN103221537A (zh) 2013-07-24
US20130243744A1 (en) 2013-09-19
US20170159095A1 (en) 2017-06-08
AU2012204241A1 (en) 2013-06-06
EP2661492A4 (en) 2015-04-15
CA2817765A1 (en) 2012-07-12

Similar Documents

Publication Publication Date Title
MX2013006234A (es) Metodo para la produccion de glicoproteinas recombinantes con semivida en circulacion incrementada en celulas de mamifero.
AR124871A2 (es) Métodos de fabricación para el control del contenido de lisina c-terminal, galactosa y ácido siálico en proteínas recombinantes
MX366155B (es) Celulas para producir iduronato-2-sulfatasa recombinante.
MX2013005654A (es) Composiciones y metodos para la produccion de acido 3-hidroxipropionico.
AR078544A1 (es) Procedimiento de cultivo de celulas de mamiferos para la produccion de proteinas
ECSP13012978A (es) Inhibidores de glucosilceramida sintasa
BR112015019997A2 (pt) Métodos de sacarificar e fermentar um material celulósico
MX339769B (es) Sistemas, metodos y composiciones para optimizar injertos enriquecidos con celulas y tejidos.
MX2015007361A (es) Produccion mediada por la proteina portadora de acilo de los derivados de acidos grasos.
MX349992B (es) Composiciones de alta concentracion de alfa-glucosidasa para el tratamiento de la enfermedad de pompe.
PE20171799A1 (es) Formulacion que comprende n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada
TN2013000427A1 (en) Modified acid alpha glucosidase with accelerated processing
BR112013017884A2 (pt) varredura de microcolônia encapsulada com gel
MX366106B (es) Composiciones y metodos para producir glucoproteinas.
WO2013136189A3 (en) Methods and materials for treatment of pompe's disease
IN2015DN00976A (es)
MY170889A (en) Car enzymes and improved production of fatty alcohols
MX2016005824A (es) Metodo de cultivo celular.
BR112014014151A2 (pt) células fúngicas e processos de fermentação
MX2015004516A (es) Procedimientos y sistemas para optimizar el sistema de cultivo de celulas de perfusion.
PH12014502870A1 (en) Method of producing recombinant iduronate-2-sulfatase
MX2022002057A (es) Variantes de enzima con propiedades de ester sintasa mejoradas.
WO2012115903A3 (en) Yeast strain for the production of proteins with modified o-glycosylation
WO2011086447A3 (en) Fermentation process for the preparation of recombinant heterologous proteins
MX2015010887A (es) Formulaciones y metodos para aumentar la produccion de proteinas recombinantes.